What ventricular mechanics reveal about afterload, cardiac performance, and the relationship between the two.
A treatment lowers right ventricular pressure in a preclinical pulmonary arterial hypertension study. That is an encouraging finding—but what does it tell us about how the treatment works?
Is the right ventricle pumping against a lower vascular load? Is it maintaining or increasing blood flow? Has ventricular remodeling improved? Or is the lower pressure accompanied by declining pump performance?
These distinctions matter because pressure is only one part of the cardiovascular response. Right ventricular pressure–volume loops help connect the pressure the heart generates with the volume it moves, providing a more complete assessment of treatment effects in PAH. Their translational relevance is supported by clinical research linking pressure–volume-derived right ventricular–pulmonary arterial coupling to outcomes in patients with PAH.
Why pressure alone does not tell the whole story
Pulmonary pressure depends on blood flow, pulmonary vascular resistance, and downstream filling pressure. Consequently, a reduction in pressure does not, by itself, establish that pulmonary vascular disease has improved. A pressure decrease accompanied by maintained cardiac output has a different physiological meaning from a pressure decrease accompanied by a substantial loss of output.
The right ventricle also adapts as disease develops. Experimental PAH studies show that increased pressure and ventricular hypertrophy can coexist with maintained stroke volume and cardiac output during a compensated phase. Pressure elevation therefore does not necessarily mean that the ventricle has already failed, just as pressure reduction does not necessarily mean that ventricular function has recovered.
For drug-development studies, the more useful question is:
Does treatment improve the relationship between the load imposed on the right ventricle and its ability to move blood through the pulmonary circulation?
What does a right ventricular pressure–volume loop add?
A pressure–volume loop plots ventricular pressure against ventricular volume throughout a cardiac cycle. With appropriate signal acquisition and volume calibration, these measurements support assessment of stroke volume, ejection fraction, cardiac output, stroke work, and systolic and diastolic ventricular mechanics. CorDynamics incorporates these measurements into studies designed to characterize cardiac performance under controlled loading conditions.
In PAH, three related—but distinct—concepts are particularly useful.
Afterload: What must the right ventricle pump against?
Effective arterial elastance, or Ea, is commonly calculated from RV end-systolic pressure divided by stroke volume:
Ea ≈ RV end-systolic pressure / stroke volume
This places pressure generation in the context of the volume ejected. A ventricle producing high pressure while ejecting a small volume experiences a different effective load from one moving a larger volume at a lower pressure. Ea is an integrated index of arterial load; it is not simply a measurement of pulmonary arterial stiffness or pulmonary vascular resistance.
For treatment assessment, a reduction in Ea supports reduced effective RV afterload. The pressure and volume components should still be examined separately to understand what drove that change.
Contractility: What can the right ventricle generate?
End-systolic elastance, or Ees, describes the end-systolic pressure–volume relationship. In a multibeat assessment, this relationship is evaluated across several cardiac cycles during a controlled change in preload, rather than inferred from a single resting pressure measurement.
Ees provides a relatively load-insensitive assessment of chamber-level contractile behavior. However, it is not a direct measurement of isolated cardiomyocyte contractility: ventricular geometry and hypertrophic remodeling also contribute to chamber mechanics.
Coupling: Is ventricular performance matched to vascular load?
The ratio Ees/Ea describes right ventricular–pulmonary arterial coupling—the relationship between ventricular contractile behavior and the load against which the ventricle ejects. Multibeat measurements of this ratio have demonstrated prognostic significance in human PAH.
An important interpretive distinction follows directly from the ratio: coupling can improve because vascular load falls, without an increase in Ees. That can be a meaningful therapeutic benefit, but it should not automatically be described as a direct positive inotropic effect. Examining the numerator and denominator is more informative than reporting the coupling ratio alone.
A practical example: connecting reduced load with favorable remodeling
Our hypoxia/Sugen reference-control work illustrates the value of combining RV pressure–volume analysis with echocardiography and structural endpoints.
In one study, rats received RAP-011, a sotatercept analog, beginning after the hypoxia phase. Echocardiography was followed by terminal RV pressure–volume analysis and organ-weight collection. This design allowed ventricular pressure and effective arterial load to be interpreted alongside right-heart size and hypertrophy.
At 5 mg/kg twice weekly, the reported changes relative to PAH vehicle included:
| Endpoint | Assessment | Change versus PAH vehicle |
| RV end-systolic pressure | Pressure–volume analysis | 42% lower |
| Effective arterial elastance, Ea | Pressure–volume analysis | 67% lower |
| RV internal diameter in diastole | Echocardiography | 31% lower |
| Pulmonary acceleration time / pulmonary ejection time, PAT/PET | Doppler echocardiography | 58% higher |
| Fulton’s Index | Terminal assessment of RV hypertrophy | 34% lower |
The value of this dataset is not simply that several endpoints changed. It is that they support a coherent interpretation: lower RV pressure and effective arterial load occurred alongside favorable changes in right-heart dimensions and hypertrophy.
That provides stronger evidence of beneficial cardiovascular effects than an isolated pressure reduction. At the same time, these results should not be stretched into a claim that direct myocardial contractility increased. The clearest interpretation is RV unloading accompanied by favorable structural remodeling.
Why a lower dP/dt is not automatically a worse result
Peak positive dP/dt—the maximum rate of ventricular pressure rise—is often treated as a straightforward indicator of contractility. In PAH, that interpretation can be misleading.
An overloaded, hypertrophied right ventricle can generate pressure more rapidly even as the disease burden increases. Experimental studies have documented increased RV dP/dt during the development of pulmonary hypertension, while isolated-heart work shows how apparent functional differences can change when ventricular mass is taken into account.
Consequently, a treatment-associated decrease in dP/dt should trigger a question, not an automatic conclusion: does it reflect impaired contractile performance, or a ventricle that no longer needs to generate the same high pressure?
Interpreting dP/dt alongside pressure, stroke volume, loading conditions, and ventricular remodeling helps distinguish those possibilities. The objective is not to make every numerical endpoint increase. It is to understand whether the overall physiological response is favorable.
Diastolic function deserves attention, too
PAH studies understandably emphasize systolic pressure and ejection, but the right ventricle must also fill between beats.
RV end-diastolic pressure and the end-diastolic pressure–volume relationship provide information about filling conditions and chamber stiffness. Experimental hypoxia/SUGEN work has shown that diastolic stiffening can develop on a different time course from hypertrophy and changes in systolic performance.
An elevated filling pressure alone does not identify its cause. Assessing pressure in relation to volume helps determine whether an apparent improvement reflects altered loading, altered chamber properties, or both.
PV loops are strongest when paired with complementary measurements
Pressure–volume analysis and echocardiography answer different questions.
Serial echocardiography can track changes in RV dimensions, wall thickness, chamber areas, and pulmonary flow patterns over time. Terminal PV analysis adds detailed assessment of ventricular mechanics at a defined disease stage or treatment endpoint. Organ weights and histopathology provide complementary evidence of cardiac and pulmonary vascular remodeling. These modalities are incorporated into CorDynamics’ PAH study capabilities.
The practical benefit is a more discriminating interpretation. Lower effective arterial load together with smaller RV dimensions and reduced hypertrophy supports a different conclusion from lower pressure without improvement in flow or structure. Conversely, a treatment that benefits ventricular performance without a large pressure reduction may still deserve attention.
The study should therefore be designed around the biological question—not simply around collecting the largest possible endpoint list.
Methodology determines how much the data can tell us
The strength of a PV dataset depends on more than obtaining recognizable loops. Volume calibration, catheter positioning, anesthesia, physiological support, loading maneuvers, and analysis methods all affect interpretation. Consensus guidance for rodent PV studies emphasizes consistent acquisition, transparent reporting, and appropriate handling of within-animal and between-animal variability.
Claims about contractility or coupling should identify how the relevant measurements were obtained. Multibeat relationships generated during preload reduction and single-beat estimates should not be presented as interchangeable measurements.
Terminology also matters. Ea is not pulmonary vascular resistance, and an RV pressure–volume catheter does not directly measure pulmonary arterial pressure. Conventional PVR calculation requires the difference between mean pulmonary arterial pressure and left atrial pressure—or an appropriate surrogate—divided by cardiac output. A ratio based on RV systolic or end-systolic pressure should be identified as an RV pressure–flow index or estimate, rather than presented as a directly measured PVR.
Moving beyond “Did the pressure fall?”
At CorDynamics, we use integrated hemodynamic and imaging approaches in models such as monocrotaline and hypoxia/Sugen PAH to evaluate pulmonary vascular load and its consequences for the right heart.
Pressure–volume loops help move the treatment question beyond whether RV pressure decreased. They provide a framework for asking how the treatment changed ventricular workload, how the ventricle responded, and whether those changes align with the broader disease phenotype.
The goal is not simply to demonstrate a lower pressure. It is to build stronger evidence that a treatment improves how the right ventricle manages pulmonary vascular disease.
